Emibetuzumab (INN ; development code LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer. It is in phase II trials for patients with non-small-cell lung cancer (NSCLC).
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.